Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 2/2020

14.03.2020 | Multiple Myeloma (P Kapoor, Section Editor)

Supportive Care in Multiple Myeloma

verfasst von: Amy Guzdar, Caitlin Costello

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

As novel therapies are expanding the life expectancy of patients with multiple myeloma, appropriate supportive care has become critical in the management of these patients. This review aims to outline the key principles of supportive care of patients with myeloma, including management of bone disease, renal disease, anemia, peripheral neuropathy, infections, and venous thromboembolism.

Recent Findings

The results from large randomized, controlled trials on the use of high-cutoff hemodialysis in the removal of free light chains in renal disease and the use of levofloxacin in the prevention of infections have recently been published. These results, along with updated guidelines from professional societies on the use of bisphosphonates and erythropoietin stimulating agents, have provided guidance on more effective management strategies for myeloma patients.

Summary

Integration of these updated guidelines and supportive care strategies into clinical practice will help to ensure quality of life for patients with myeloma.
Literatur
2.
Zurück zum Zitat Kazandijan D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016;43(6):676–81.CrossRef Kazandijan D. Multiple myeloma epidemiology and survival, a unique malignancy. Semin Oncol. 2016;43(6):676–81.CrossRef
3.
Zurück zum Zitat Shortt CP, Gleeson TG, Breen KA, McHugh J, O’Connell MJ, O’Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192(4):980.CrossRef Shortt CP, Gleeson TG, Breen KA, McHugh J, O’Connell MJ, O’Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192(4):980.CrossRef
4.
Zurück zum Zitat Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.PubMed Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.PubMed
5.
Zurück zum Zitat Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;16(5):CD003188. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;16(5):CD003188.
6.
Zurück zum Zitat Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270.CrossRef Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(25):2270.CrossRef
7.
Zurück zum Zitat Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8):1047.CrossRef Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81(8):1047.CrossRef
8.
Zurück zum Zitat Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464.CrossRef Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464.CrossRef
9.
Zurück zum Zitat •• Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases. A Randomized Clinical Trial. JAMA. 2017;317(1):48–58. A potentially practice-changing large phase III study that found non-inferiority when dosing zoledronic acid every 12 weeks when compared to the standard every 4 weeks. •• Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases. A Randomized Clinical Trial. JAMA. 2017;317(1):48–58. A potentially practice-changing large phase III study that found non-inferiority when dosing zoledronic acid every 12 weeks when compared to the standard every 4 weeks.
10.
Zurück zum Zitat •• Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized, controlled phase 3 study. Lancet Oncol. 2018;19(3):370. A large phase III study that found non-inferiority of denosumab when compared to zoledronic acid, and found significantly less renal adverse events in patients treated with denosumab when compared to zoledronic acid. •• Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized, controlled phase 3 study. Lancet Oncol. 2018;19(3):370. A large phase III study that found non-inferiority of denosumab when compared to zoledronic acid, and found significantly less renal adverse events in patients treated with denosumab when compared to zoledronic acid.
11.
Zurück zum Zitat Terpos E, García-Sanz R, Shimizu K, Willenbacher W, Glennane A, Dai T, Pasteiner W, Raje NS. Progression-free survival analysis of denosumab vs zoledronic acid in intent to transplant multiple myeloma patients based on treatment regimen and baseline characteristics. American Society of Hematology Conference; 2019 Dec 7–9; Orlando, FL; Abstract 606. Terpos E, García-Sanz R, Shimizu K, Willenbacher W, Glennane A, Dai T, Pasteiner W, Raje NS. Progression-free survival analysis of denosumab vs zoledronic acid in intent to transplant multiple myeloma patients based on treatment regimen and baseline characteristics. American Society of Hematology Conference; 2019 Dec 7–9; Orlando, FL; Abstract 606.
12.
Zurück zum Zitat Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–7.CrossRef Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–7.CrossRef
13.
Zurück zum Zitat Huber FX, McArthur N, Tanner M, Gritzbach B, Schoierer O, Rothfischer W, et al. Kyphoplasty for patients with multiple myeloma is a safe surgical procedure: results from a large patient cohort. Clin Lymphoma Myeloma. 2009;9(5):375–80.CrossRef Huber FX, McArthur N, Tanner M, Gritzbach B, Schoierer O, Rothfischer W, et al. Kyphoplasty for patients with multiple myeloma is a safe surgical procedure: results from a large patient cohort. Clin Lymphoma Myeloma. 2009;9(5):375–80.CrossRef
14.
Zurück zum Zitat Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347.CrossRef Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347.CrossRef
15.
Zurück zum Zitat Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8(11):2007–17.CrossRef Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc Nephrol. 2013;8(11):2007–17.CrossRef
16.
Zurück zum Zitat Manohar S, Nasr SH, Leung N. Light chain cast nephropathy: practical considerations in the management of myeloma kidney- what we know and what the future may hold. Curr Hematol Malig Rep. 2018;13(3):220–6.CrossRef Manohar S, Nasr SH, Leung N. Light chain cast nephropathy: practical considerations in the management of myeloma kidney- what we know and what the future may hold. Curr Hematol Malig Rep. 2018;13(3):220–6.CrossRef
17.
Zurück zum Zitat Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–36.CrossRef Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22(6):1129–36.CrossRef
18.
Zurück zum Zitat Hutchison CA, Cockwell P, Moroz V, Bradwell A, Fifer L, Gillmore JD, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):217–28.CrossRef Hutchison CA, Cockwell P, Moroz V, Bradwell A, Fifer L, Gillmore JD, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):217–28.CrossRef
19.
Zurück zum Zitat Bridoux F, Carron PL, Pegourie B, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA. 2017;318:2099–110.CrossRef Bridoux F, Carron PL, Pegourie B, et al. Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial. JAMA. 2017;318:2099–110.CrossRef
20.
Zurück zum Zitat Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.PubMed Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.PubMed
21.
Zurück zum Zitat Untch M, von Minckwitz G, Konecny GE, Conra U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis. Ann Oncol. 2011;22(9):1999–2006.CrossRef Untch M, von Minckwitz G, Konecny GE, Conra U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis. Ann Oncol. 2011;22(9):1999–2006.CrossRef
22.
Zurück zum Zitat Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–210.CrossRef Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–210.CrossRef
23.
Zurück zum Zitat Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12(1):102–10.CrossRef Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12(1):102–10.CrossRef
24.
Zurück zum Zitat Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113.CrossRef Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113.CrossRef
25.
Zurück zum Zitat Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib and bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661.CrossRef Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib and bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661.CrossRef
26.
Zurück zum Zitat Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;5:e338.CrossRef Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;5:e338.CrossRef
27.
Zurück zum Zitat Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219.CrossRef Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23(36):9219.CrossRef
28.
Zurück zum Zitat Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107.CrossRef Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107.CrossRef
29.
Zurück zum Zitat •• Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomised phase 3 trial. Lancet. 2019;20(12):1760–72. A large phase III trial that demonstrated a survival benefit in patients receiving levofloxacin prophylaxis in patients with newly diagnosed multiple myeloma. This is potentially practice changing for clinicians. •• Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomised phase 3 trial. Lancet. 2019;20(12):1760–72. A large phase III trial that demonstrated a survival benefit in patients receiving levofloxacin prophylaxis in patients with newly diagnosed multiple myeloma. This is potentially practice changing for clinicians.
30.
Zurück zum Zitat Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059–63.CrossRef Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059–63.CrossRef
31.
Zurück zum Zitat Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582.CrossRef Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582.CrossRef
32.
Zurück zum Zitat Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933–9.CrossRef Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933–9.CrossRef
33.
Zurück zum Zitat Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol. 2019:JCO1901461. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol. 2019:JCO1901461.
Metadaten
Titel
Supportive Care in Multiple Myeloma
verfasst von
Amy Guzdar
Caitlin Costello
Publikationsdatum
14.03.2020
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 2/2020
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-020-00570-9

Weitere Artikel der Ausgabe 2/2020

Current Hematologic Malignancy Reports 2/2020 Zur Ausgabe

Chronic Lymphocytic Leukemias (N Jain, Section Editor)

Is There a Role for Chemotherapy in the Era of Targeted Therapies?

Myeloproliferative Neoplasms (B Stein, Section Editor)

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults

Stem Cell Transplantation (R Maziarz, Section Editor)

Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy

Multiple Myelomas (P Kapoor, Section Editor)

Extramedullary Disease in Multiple Myeloma

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.